Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma

Link, 2013, Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic specialized program of research excellence molecular epidemiology resource, J Clin Oncol, 31, 3272, 10.1200/JCO.2012.48.3990

Casulo, 2015, Transformed follicular non-Hodgkin lymphoma, Blood, 125, 40, 10.1182/blood-2014-04-516815

Al-Tourah, 2008, Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma, J Clin Oncol, 26, 5165, 10.1200/JCO.2008.16.0283

Montoto, 2007, Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma, J Clin Oncol, 25, 2426, 10.1200/JCO.2006.09.3260

Chen, 2001, Autotransplants for histologically transformed follicular non-Hodgkin’s lymphoma, Br J Haematol, 113, 202, 10.1046/j.1365-2141.2001.02705.x

Eide, 2011, High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study, Br J Haematol, 152, 600, 10.1111/j.1365-2141.2010.08519.x

Villa, 2013, Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group, J Clin Oncol, 31, 1164, 10.1200/JCO.2012.44.0693

Ban-Hoefen, 2013, Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database, Br J Haematol, 163, 487, 10.1111/bjh.12570

Friedberg, 1999, Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies, Biol Blood Marrow Transplant, 5, 262, 10.1053/bbmt.1999.v5.pm10465106

Vose, 2000, Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas, J Clin Oncol, 18, 1316, 10.1200/JCO.2000.18.6.1316

Kaminski, 2001, Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas, J Clin Oncol, 19, 3918, 10.1200/JCO.2001.19.19.3918

Witzig, 2002, Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma, J Clin Oncol, 20, 2453, 10.1200/JCO.2002.11.076

Fisher, 2005, Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin’s lymphomas, J Clin Oncol, 23, 7565, 10.1200/JCO.2004.00.9217

Morschhauser, 2013, 90Yttrium–ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial, J Clin Oncol, 31, 1977, 10.1200/JCO.2012.45.6400

Zinzani, 2012, Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma), Ann Oncol, 23, 805, 10.1093/annonc/mdr633

Press, 2013, Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine–tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016, J Clin Oncol, 31, 314, 10.1200/JCO.2012.42.4101

Friedberg, 2014, R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433, Br J Haematol, 166, 382, 10.1111/bjh.12906

Zinzani, 2008, Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ), Lancet Oncol, 9, 352, 10.1016/S1470-2045(08)70039-1

Montoto, 2015, Treatment of patients with transformed lymphoma, Hematology, 2015, 625, 10.1182/asheducation-2015.1.625

Bennett, 2005, Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab, Blood, 105, 4576, 10.1182/blood-2004-12-4690

Czuczman, 2007, Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy, J Clin Oncol, 25, 4285, 10.1200/JCO.2006.09.2882

Vincent, 2010

Hurria, 2015, Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement, J Clin Oncol, 33, 3826, 10.1200/JCO.2015.63.0319

Hurria, 2005, Developing a cancer-specific geriatric assessment: a feasibility study, Cancer, 104, 1998, 10.1002/cncr.21422

Hurria, 2011, Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study, J Clin Oncol, 29, 3457, 10.1200/JCO.2011.34.7625